1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS

1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS

312767

1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS

Immunic Therapeutics has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we advance our lead asset, vidofludimus calcium [IMU-838], into active clinical phase 3 development,” Daniel Vitt, PhD, Immunic’s president and CEO, said in a press release. Vitt added…

You must be logged in to read/download the full post.